Key result
Simultaneous loss of HOIL-1L and SHARPIN ubiquitin-binding synergistically impairs NF-κB activation and cell death protection.
Why the study?
The synergistic effects of the two NZF domains of LUBAC accessory subunits HOIL-1L and SHARPIN on LUBAC function remain unclear.
The ubiquitin-binding activity of the NZF domains of HOIL-1L and SHARPIN cooperatively regulates LUBAC functions, suggesting a potential therapeutic strategy for targeting increased LUBAC activity in diseases such as cancer.
Animal data implicate NZF ubiquitin-binding in LUBAC regulation; leaves open translation to cancer therapies in humans.
The linear ubiquitin chain assembly complex (LUBAC) plays crucial roles in NF-κB signaling and protection against cell death by generating linear ubiquitin chains. Its accessory subunits, HOIL-1L and SHARPIN, regulate LUBAC function by binding to ubiquitin chains via their Npl4 zinc finger (NZF) domains. However, the synergistic effects of the two NZF domains on LUBAC function remain unclear. Here, we demonstrate that the ubiquitin-binding activity of the two NZF domains cooperatively regulates LUBAC functions. Simultaneous loss of the ubiquitin-binding activity of the NZF domains profoundly impaired both NF-κB activation and cell death protection functions. HOIL-1L NZF robustly binds to linear ubiquitin chains, whereas SHARPIN NZF binds to Lys(K)63-linked ubiquitin chains in addition to linear chains. Binding of both NZF domains to linear ubiquitin chains regulated NF-κB signaling, whereas SHARPIN NZF predominantly regulated the cell death protection function independently of the ubiquitin chain type, K63-linked or linear ubiquitin. However, concomitant loss of linear ubiquitin binding by HOIL-1L NZF drastically impaired cell death protection. A screen of compounds capable of inhibiting binding between HOIL-1L NZF and linear ubiquitin chains identified a small compound that inhibited SHARPIN NZF as well as HOIL-1L NZF binding to linear ubiquitin chains, supporting the synergistic effect of the two NZF domains on cell death protection and suggesting a potential therapeutic strategy for targeting increased LUBAC activity in diseases such as cancer.
No takes yet. Share an insight, caveat, or question.
Toda et al. (2024) studied LUBAC function in NF-κB signaling and cell death. Mutation of NZF domains (HOIL-1L and SHARPIN) and small molecule inhibitors (FSL0717, FSL0720) vs. Wild-type cells / DMSO was evaluated on NF-κB activation and cell death protection. Simultaneous loss of the ubiquitin-binding activity of the NZF domains of HOIL-1L and SHARPIN synergistically impaired both NF-κB activation and cell death protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: